|
|
Office Locations:
|
512 W. 22nd Street, 5th Floor
New York, NY 10011
Phone: 917-832-1832
| |
|
|
|
|
|
|
Life Sciences & Healthcare
Medical Device
|
|
|
|
Catalio was founded in 2020 by George Petrocheilos and R. Jacob Vogelstein to invest in the next generation of category-defining life sciences companies around the globe. The mission is to produce extraordinary returns by creating and sustaining life sciences companies that combine the best science and technology with the best management teams and financial syndicates. To achieve this objective, they work with the world's best scientists, engineers and clinicians to identify breakthrough biotechnologies; co-invest with top-tier funds; and recruit A-list talent from our collective networks. The firm focuses on biomedical technology companies developing next-generation drugs, devices and diagnostics.
|
|
|
|
|
Investment Firm Key
VC = Venture Capital
PE = Private Equity
A = Angel
I = Incubator
MB = Merchant Bank
VD = Venture Debt
FI = Family Investment Office
FOF = Fund of Funds
ED = Economic Development Office
TT = Technology Transfer Office
CVC = Corporate Venture Capital
SEC = Secondary Purchaser
HF = Hedge Fund/Mutual Fund
|
|
| COMPANY STAGE | REVENUE |
| Venture Capital | |
Seed Stage
(includes "pre-seed," or
concept stage) | No Revenue |
| Early Stage | Minimal
Revenue |
Growth Stage
(also called Mid-stage) | $2M-$7M |
Expansion Stage
(also called Late-stage) | $7M and greater |
| Private Equity | |
| Lower Middle Market | $10M-$249M |
| Middle Market | $250M-$499M |
| Upper Middle Market | $500M-$1B |
| Large Cap | >$1B |
|
|
|
|
|
